SAI Life Sciences is a strategic Discovery and Contract Development & Manufacturing Service organization, with a broad service platform tailored to deliver "Solutions that Add Up" for the diverse needs of pharma and biotech companies. Its mission is to help its partners develop innovative medicines quicker and at lower cost by providing reliable research & manufacturing solutions.
High quality services in Discovery, CMC development and API supply to global innovators
Established in 1999, SAI has focused on building expert core capabilities in chemistry - synthetic chemistry, medicinal chemistry, process development, scale-up chemistry, analytical and manufacturing and has effectively expanded to provide high-quality integrated services in DMPK, toxicology and formulation development.
SAI is a growing company averaging 30% annual growth in revenue since 2005 and has strong financial backing from VC groups such as Sequoia and MPM Capital.
The scientific leadership team brings broad and extensive experience from successful tenures at US and EU biopharmaceutical companies. They play a critical role in managing the success of our partnership and in mentoring the entire organization to become the ideal partner. The workforce today is over 1100 with a high percentage of skilled scientists.
Delivery & project managers ensure a consistent and effective process throughout the project life cycle and beyond
Efficient program management is a key focus area for SAI in delivering customer projects. A team of experienced Delivery & Project Managers work closely with development and operational groups to ensure timelines are met ensuring a consistent and effective process throughout the project life cycle and beyond.
SAI has made significant strategic investments in state-of-the-art laboratory and manufacturing facilities located in Hyderabad and Pune in India. The research infrastructure includes ~200,000 sq. ft of discovery and Process R&D lab space. The 2 manufacturing sites bring together over 180m3 of manufacturing capacity, to produce KSM, cGMP intermediates and APIs for clinical trials and commercial drugs. The plants are fully flexible offering a wide variety of reaction capabilities and handling of complex syntheses at multiple scales.
SAI has developed a range of complex APIs such as Prostaglandins and vitamin D derivatives. In addition SAI supplies a range of oligonucleotide intermediates.
High quality standards across all SAI units and governed by corporate QA policies
Global regulatory and quality standards (such as ICH Q7, 21 CFR Part 210, 211, EU GMPs, and GMP guidelines from a.o. TGA, PMDA, TPD, WHO) have been used while designing the quality systems and compliance standards at SAI as evidenced by more than 300 successful client/third party audits (full cGMP audits, regulatory audits; USFDA, Mexican authorities, QP audits etc). The quality standards are harmonized across all SAI units and governed by Corporate QA policies.
SAI has a culture of Customer First, with a clear Focus on Fast, Timely and Quality Delivery; and commitment to exceed Environmental & Safety Regulations at all facilities.
Please contact our dedicated Business Development staff in Europe & the USA to learn more about our Solutions.